Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sidney Kahn IV

Vascular & Interventional Radiology Springfield, MA Medical Doctor

NPI 1750599700 CMS profile 306370

3500 Main St, Suite 201, Springfield, MA 01107

Open in the dashboard

General payments

$55,150

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sidney Kahn IV of Springfield, MA is reported in the CMS Open Payments database as having received $55,150 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $826 15
2024 General $4,289 35
2023 General $8,169 32
2022 General $11,097 34
2021 General $15,593 10
2020 General $13,170 21
2019 General $2,005 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sidney Kahn IV
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Sidney Kahn IV were reported at $826. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Sidney Kahn IV Vascular & Interventional Radiology median Middle half National median
2019 $2,005 $422 $125–$1,555 $163
2020 $13,170 $200 $68–$652 $114
2021 $15,593 $280 $99–$866 $132
2022 $11,097 $433 $137–$1,497 $149
2023 $8,169 $506 $152–$2,019 $160
2024 $4,289 $556 $175–$1,930 $164
2025 $826 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $43,050 6 payments
  2. AbbVie, Inc. $6,912 13 payments
  3. Medtronic, Inc. $2,064 34 payments
  4. Boston Scientific Corporation $588 51 payments
  5. Bard Peripheral Vascular, Inc. $301 5 payments
  6. Janssen Pharmaceuticals, Inc $267 10 payments
  7. Abbott Laboratories $265 15 payments
  8. Tactile Systems Technology Inc $263 5 payments
  9. Medtronic USA, Inc. $161 2 payments
  10. Philips Electronics North America Corporation $152 8 payments
  11. Other $1,128 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $22,360 3 payments
  2. Long term medical supply or device loan $20,708 3 payments
  3. Food and Beverage $5,405 161 payments
  4. Consulting Fee $5,400 1 payment
  5. Travel and Lodging $1,276 5 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $35,708 4 payments
  2. Auryon $7,250 1 payment
  3. DUOPA $6,912 13 payments
  4. KYPHON EXPRESS II KYPHOPAK TRAY $981 15 payments
  5. ELLIPSYS VASCULAR ACCESS SYSTEM $462 10 payments
  6. XARELTO $267 10 payments
  7. ELUVIA $184 18 payments
  8. RotarexS 6 F x 135 cm $171 2 payments
  9. OSTEOCOOL RF ABLATION SYSTEM $171 3 payments
  10. Abre $161 2 payments
  11. Other $3,222 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

135

Median for Diagnostic Radiology: 24

Drug cost

$49,976

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 48 $34,476
Eliquis Apixaban Brand 21 $14,651
Clopidogrel Clopidogrel Bisulfate Brand 66 $848

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 162 billing codes

Paid by Medicare

$1,040,692

Of which drugs: $2,849

Medicare patients

465

Average age 75

Services billed

11,580

244 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Chronic kidney disease 44%
Diabetes 43%
Ischemic heart disease 36%
Heart failure 34%
Atrial fibrillation 31%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 89 7,458 $792
Injection, cefazolin sodium, 500 mg J0690 Office 120 272 $167
Injection, fentanyl citrate, 0.1 mg J3010 Office 146 174 $124
Injection, vancomycin hcl, 500 mg J3370 Office 23 42 $73
Injection, hydromorphone, up to 4 mg J1170 Office 14 15 $43
Injection, ketorolac tromethamine, per 15 mg J1885 Office 34 70 $36
Injection, midazolam hydrochloride, per 1 mg J2250 Office 141 270 $29
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 34 38 $25
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 13 60 $4
Injection, hydromorphone, 0.1 mg J1171 Office 16 17 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DefenCath
  • CorMedix Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record